By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


PharmaEngine, Inc. 

16F, 237 Sung-Chiang Road

Taipei  Taiwan  104  Republic of China
Phone: 886-2-2515-8228 Fax: 886-2-2515-7558



Company News
PharmaEngine, Inc. Announces Phase 2 PEPCOL Study Presented At The 2015 American Society of Clinical Oncology GI Of PEP02 (MM-398) In Combination With 5-FU/LV In Unresectable Metastatic Colorectal Cancer 1/21/2015 10:58:16 AM
PharmaEngine, Inc. Announces Expanded Analyses Of Phase 3 MM-398 NAPOLI-1 Study Presented At The 2015 American Society of Clinical Oncology GI Substantiate The Positive Results Of MM-398 In Combination With 5-FU/LV 1/19/2015 11:14:02 AM
PharmaEngine, Inc. Will Join Nanobiotix' Pivotal Trial For NBTXR3 In Soft Tissue Sarcoma To Accelerate Its Development In Asia-Pacific 10/8/2014 7:10:22 AM
PharmaEngine, Inc. And Merrimack Amend MM-398 License Agreement 9/26/2014 8:11:08 AM
PharmaEngine, Inc. Announces Achieving Patient Enrollment Goal in the Phase III Metastatic Pancreatic Cancer Study of PEP02 (MM-398) 8/29/2013 10:14:59 AM
PharmaEngine, Inc. Release: Studies of Nanoliposomal Irinotecan (PEP02, MM-398) in Late Stage Pancreatic Cancer and Gastric Cancer Published in British Journal of Cancer and Annals of Oncology 8/28/2013 10:47:42 AM
PharmaEngine, Inc. and Guangzhou BeBetter Medicine Technology Signed a Collaboration and Research Agreement 1/3/2013 9:25:24 AM
PharmaEngine, Inc. Nabs Rights to Nanobiotix's Nanoparticle Radiotherapy Booster for Up to $57 Million 8/6/2012 7:54:44 AM
PharmaEngine, Inc. and Merrimack Pharmaceuticals Inc. Enter into a Licensing and Collaboration Agreement; PharmaEngine Eligible for $220 Million Upfront and Milestone Payments Plus Royalties 5/9/2011 6:57:44 AM
PharmaEngine, Inc. Receives Approval of US IND Application for a Phase II Study of PEP02 (Liposome Irinotecan Injection) in Pancreatic Cancer 12/3/2008 9:21:16 AM